Skip to content

NASDAQ · mid · thesis board

IONS Ionis Pharmaceuticals

Antisense oligonucleotide platform

View race

Thesis

Editorial summary — not a primary filing

Antisense platform with partnered neurology and cardiometabolic shots.

Next gate

2026-12-08EstimatedPh3 readout

Metabolic Phase 3

52 days · Estimated: Estimated window

Survive-to-Event

ok

Cash covers the next gate with ~22 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~722d)100%
Days to gate (52d)7%
Show math

$1.9B cash ÷ $80M/mo burn ≈ 722 days. Source: curated SEC quarter figures.

Cash $1.9B as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
NVOPh3okLLYPh3okAMGNPh3ok

Risks

  • Partner dependence
  • Competitive modalities
  • Trial outcomes
  • Royalty mix

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT05552326as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01